Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

Data ReadoutpositiveEP-104GIPositive

AI Analysis

Summary

Eupraxia Pharmaceuticals reported positive 52-week data from its Phase 1b/2a RESOLVE trial of EP-104GI for eosinophilic esophagitis, demonstrating long duration of response, high remission rates, and good tolerability in the highest dose cohort.

Clinical Trial Data

Phase

1b/2a

Outcome Details

52-week data from highest dose cohort showed long duration of response, high remission rates and tolerability

Importance:6/10

Sentiment:

0.65

clinical_trial_dataphase_1b_2aeosinophilic_esophagitisdrug_delivery

Related Companies

$EPRX

Read the original article

Published by GlobeNewswire Pharma on September 30, 2026 12:00 PM

Read Original